NYXH Nyxoah S.A.
USHealthcareAs of 2026-07-10 16:00
Why NYXH matters now
Nyxoah S.A. (NYXH) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.71 with +2.40% on the session and $67.7M in market capitalization; recent performance reads 1-month -43.06% and YTD -65.22%.
The latest financial table shown here is Q1 2026, with revenue of $7.4M, net income of $-18.4M, and EPS of $-0.37. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -132.7%.
The latest indexable market news headline is "Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day" from MarketBeat.
Additional event context on this page matters because analyst consensus is Hold with a median target of $5.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.67
P/S
3.38
EV/EBITDA
-1.02
DCF Value
$-90.69
FCF Yield
-132.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
48.3%
Operating Margin
-527.2%
Net Margin
-527.8%
ROE
-164.4%
ROA
-87.9%
ROIC
-116.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $7.4M | $-18.4M | $-0.37 |
| Q4 2025 | $5.6M | $-23.5M | $-0.59 |
| FY 2025 | $10.0M | $-90.1M | $-2.37 |
| Q3 2025 | $2.0M | $-23.6M | $-0.63 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$3.00 - $7.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
BE
Exchange
—
Beta
0.89
Nyxoah S.A. is a medical technology company dedicated to developing and bringing to market therapies for sleep disordered breathing conditions. Its flagship offering is the Genio system, a CE-Marked, patient-focused hypoglossal neurostimulation therapy that addresses moderate to severe obstructive sleep apnea. Established in 2009, the company maintains its headquarters in Mont-Saint-Guibert, Belgium.